首页> Clinical Pharmacology and Therapeutics> EVALUATION OF INCLUSION/ EXCLUSION CRITERIA AND RESULTING DOSING RECOMMENDATIONS IN PRODUCT LABELING FOR PATIENTS WITH KIDNEY DISEASE.

EVALUATION OF INCLUSION/ EXCLUSION CRITERIA AND RESULTING DOSING RECOMMENDATIONS IN PRODUCT LABELING FOR PATIENTS WITH KIDNEY DISEASE.

导出原文传递

翻译打印收藏纠错

作者： Jiang, Y. T. ^[1] ; Ramamoorthy, A. ^[2] ; Florian, J. ; Madabushi, R.

作者单位： US FDA, Silver Spring, MD USA ^[1] Rutgers State Univ, New Brunswick, NJ USA ^[2]

发布时间 2020-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical Pharmacology and Therapeutics

2019年105卷Suppl.1期

S60-S60页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Clinical Pharmacology and Therapeutics

2019年105卷Suppl.1期

S60-S60页

检索历史清除

EVALUATION OF INCLUSION/ EXCLUSION CRITERIA AND RESULTING DOSING RECOMMENDATIONS IN PRODUCT LABELING FOR PATIENTS WITH KIDNEY DISEASE.

Clinical Pharmacology and Therapeutics

相似文献

Clinical Pharmacology and Therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

EVALUATION OF INCLUSION/ EXCLUSION CRITERIA AND RESULTING DOSING RECOMMENDATIONS IN PRODUCT LABELING FOR PATIENTS WITH KIDNEY DISEASE.

Clinical Pharmacology and Therapeutics

相似文献

Clinical Pharmacology and Therapeutics

相关期刊

检索历史清除